

December 1, 2005

MEDICAID DRUG REBATE PROGRAM

RELEASE #139

For State Medicaid Directors

VINCE POWELL RETIRES

After 32 years of Federal service, Vince is retiring effective January 3, 2006. Vince has been with the Drug Rebate Program since its inception in 1990 and was instrumental in implementing the operational aspects of the program. After many years of serving as the lead analyst for drug rebate operations, Vince became the Technical Director of the program and has served in that capacity for the remainder of his career. In addition to his operational and Technical Director duties, Vince played an integral part in the Dispute Resolution Program for many years.

Vince asked that his appreciation for the many great working relationships developed over these years be acknowledged.

UTILIZATION DISCREPANCY REPORT

Effective immediately, we are discontinuing the Min/Max/Mean portion of the Utilization Discrepancy Report. This part of the report no longer serves the needs of the program. This report will now only contain the utilization rejections. If you should receive any Min/Max/Mean reports regarding your utilization, please disregard them.

DELETED NDC FROM THE MDR SYSTEM

NDC 00065-0083-15, Enuclene, will be deleted from the drug rebate program effective January 1, 2006 (May 2006 CMS tape) because it is a device and therefore not eligible for rebate.

DELETED PRODUCTS - NO TERMINATION DATE

It has come to our attention that some states are requesting termination dates from labelers for products that have been deleted from the drug rebate program. When CMS deletes products from the drug rebate program a termination date is not required. Please note that labelers are still marketing these products and therefore can not provide you with a termination date.

UPDATES TO THE OPERATIONAL TRAINING GUIDE

Pages O2 and O4 are revised to remove Vince Powell as an operational staff member and as appropriate substitute other operational staff. Page O5 is updated to change the contact for region VII and to correct the exclusion of Utah in Region VIII. Please share this information with the appropriate staff and replace these pages in your guide.

NEW LABELERS

<u>Labeler Name/Labeler Code</u>	<u>Mandatory Coverage Date</u>	<u>Optional Coverage Date</u>
Solstice Neurosciences, Inc. (Labeler code 10454)	January 1, 2006	October 18, 2005
Brighton Pharmaceuticals, Inc. (Labeler code 10914)	January 1, 2006	August 22, 2005
Advancis Pharmaceutical (Labeler Code 11042)	January 1, 2006	August 22, 2005
Monte Sano Pharmaceuticals, Inc. (Labeler code 12162)	January 1, 2006	October 21, 2005
AR Scientific, Inc. (Labeler Code 13310) 2005	January 1, 2006	September 14,
Barrier Therapeutics (Labeler Code 13478)	January 1, 2006	October 28, 2005
FSC Laboratories, Inc. (Labeler Code 13551)	January 1, 2006	August 31, 2005
Forum Products, Inc. (Labeler Code 13863)	January 1, 2006	October 28, 2005
Auriga Pharmaceuticals, LLC (Labeler code 14629)	April 1, 2006	November 5, 2005

NEW LABELERS (Con't)

<u>Labeler Name/Labeler Code</u>	<u>Mandatory Coverage Date</u>	<u>Optional Coverage Date</u>
GSP Company (Labeler Code 15020)	January 1, 2006	September 9, 2005
Creekwood Pharmaceutical, Inc. (Labeler code 15310)	January 1, 2006	November 1, 2005
Hampton-Laine, LLC (Labeler Code 15704)	October 1, 2005	September 16, 2005
Baxter Healthcare Corporation (Labeler code 67108)	January 1, 2006	September 29, 2005
Critical Therapeutics (CRTX) (Labeler code 68734)	January 1, 2006	October 24, 2005

REINSTATED LABELER

Optics Laboratory Inc., labeler code 64108, has signed a new rebate agreement and is reinstated in the drug rebate program effective 01/01/2006. Due to special circumstances, this reinstated labeler has an optional effective date of August 3, 2005.

Contact information for new/reinstated labelers is attached for your convenience.

TERMINATED LABELERS

The following labeler codes are being terminated effective January 1, 2006:

Aventis Pharmaceuticals (Labeler Code 00070); and
ABG Laboratories, Inc. (Labeler Code 60999).

OTHER ATTACHMENT

A copy of the current listing of the 91-day treasury bill auction rates beginning with the period August 9, 2004, is attached.

Please remember to direct your drug rebate questions to a staff member listed in section “O” of the Medicaid Drug Rebate Operational Training Guide.

/s/

Edward C. Gendron
Director
Finance, Systems and Budget Group

5 Attachments

cc:
All State Drug Rebate Technical Contacts
All Regional Administrators

CMS DRUG REBATE PROGRAM

Area Code 410



OPERATIONS

Cindy Bergin	786-1176	cynthia.bergin@cms.hhs.gov
Tamara Bruce	786-1519	tamara.bruce@cms.hhs.gov
Chris Holmes	786-3328	christene.holmes@cms.hhs.gov
Karen Leshko	786-1291	karen.leshko@cms.hhs.gov
Sue Williams	786-3334	susan.williams@cms.hhs.gov

POLICY

Kim Howell	786-6762
Madlyn Kruh	786-3239
Bernadette Leeds	786-9463
Christina Lyon	786-3332
Larry Reed (Technical Director)	786-3325
Yolanda Reese	786-9898
Gail Sexton	786-4583
Marge Watchorn	786-4361

SYSTEM MAINTENANCE

E-mail inquiries to: MDRtech@cms.hhs.gov

DISPUTE RESOLUTION PROGRAM

Sue Gaston	786-6918	susan.gaston@cms.hhs.gov
Tamara Bruce	786-1519	tamara.bruce@cms.hhs.gov
Diane Dunstan	303-844-7040	diane.dunstan@cms.hhs.gov



FAX

786-0390 – Operations
786-5882 or 786-9004 - Policy

WEBSITE www.cms.hhs.gov/medicaid/drugs/drughmpg.asp

**CMS DRUG REBATE PROGRAM
PRIMARY FUNCTIONS/CONTACT PERSON**

Primary Function

Contact Person

Contact Changes (labelers and states)	Karen Leshko
CPI-U Values	Karen Leshko
Data Edit Reports	Karen Leshko, Tamara Bruce Cindy Bergin, Sue Williams
Data Submission (labelers)	Karen Leshko, Sue Williams Tamara Bruce, Cindy Bergin
Data Submission (states)	Cindy Bergin, Tamara Bruce Sue Williams, Karen Leshko
Diskette Installation/Problems	MDRtech@cms.hhs.gov
Dispute Resolution	Sue Gaston, Tamara Bruce
HIV/AIDS Drugs	Marge Watchorn
Interest Calculation	Tamara Bruce, Cindy Bergin Sue Williams, Karen Leshko
Invoice	Sue Williams, Cindy Bergin
Policy Issues (general)	Kim Howell, Christina Lyon, Gail Sexton, Marge Watchorn, Bernadette Leeds, Yolanda Reese, Madlyn Kruh
Prior Quarter Adjustment Statement	Sue Williams
Prior Period Adjustments	Tamara Bruce, Sue Williams Karen Leshko, Cindy Bergin
Reconciliation of State Invoice	Sue Williams
State Tape	MDRtech@cms.hhs.gov
T-bill Rates	Karen Leshko
Training Guide	Sue Williams
VHCA/340B Drug Pricing	Marge Watchorn

Regional Office Drug Rebate Dispute Resolution Program Coordinators

Analysts	E-mail	Phone #	States
Region I – Boston Ray Porter	raymond.porter@cms.hhs.gov	(617) 565-1260	Connecticut, New Hampshire, Maine, Massachusetts, Rhode Island, Vermont
Region II – N.Y. Robert Cochrane	robert.cochrane@cms.hhs.gov	(212) 616-2420	New York, New Jersey
Region III-Phil. Jennifer Quinn	jennifer.quinn@cms.hhs.gov	(215) 861-4174	Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia
Region IV - Atlanta Jessie Spillers Elaine Elmore	jessie.spillers@cms.hhs.gov elaine.elmore@cms.hhs.gov	(404) 562-7418 (404) 562-7408	Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee
Region V - Chicago Claudia Simonson	claudia.simonson@cms.hhs.gov	(312) 353-2115	Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin
Region VI - Dallas Mike Jones	michael.jones@cms.hhs.gov	(214) 767-6279	Arkansas, Louisiana, New Mexico, Oklahoma, Texas
Region VII - Kansas City Mandy Hanks	mandy.hanks@cms.hhs.gov	(816) 426-6424	Iowa, Kansas, Missouri, Nebraska
Region VIII – Denver *Diane Dunstan	diane.dunstan@cms.hhs.gov	(303) 844-7040	Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming
Region IX – San Francisco Michael Sullivan	michael.sullivan@cms.hhs.gov	(415) 744-3589	Arizona, California, Hawaii, Nevada
Region X - Seattle Maria Garza	maria.garza@cms.hhs.gov	(206) 615-2542	Alaska, Idaho, Oregon, Washington

WEEKLY U.S. T-BILL INVESTMENT RATE
 weekly 91-day treasury bill auction rates

Date of Auction	Invest. Rate	Date of Auction	Invest. Rate	Date of Auction	Invest. Rate
08-09-04	1.497	03-07-05	2.767	10-03-05	3.606
08-16-04	1.498	03-14-05	2.792	10-11-05	3.714
08-23-04	1.541	03-21-05	2.859	10-17-05	3.875
08-30-04	1.607	03-28-05	2.839	10-24-05	3.942
09-06-04	1.663	04-04-05	2.792	10-31-05	3.983
09-13-04	1.671	04-11-05	2.767	11-07-05	3.963
09-20-04	1.716	04-18-05	2.864	11-14-05	4.004
09-27-04	1.741	04-25-05	2.941	11-21-05	4.034
10-04-04	1.716	05-02-05	2.931		
10-12-04	1.711	05-09-05	2.911		
10-18-04	1.803	05-16-05	2.859		
10-25-04	1.890	05-23-05	2.957		
11-01-04	1.987	05-31-05	2.998		
11-08-04	2.084	06-06-05	3.029		
11-15-04	2.115	06-13-05	3.039		
11-22-04	2.197	06-20-05	3.029		
11-29-04	2.380	06-27-05	3.147		
12-06-04	2.253	07-05-05	3.214		
12-13-04	2.243	07-11-05	3.204		
12-20-04	2.223	07-18-05	3.292		
12-27-04	2.269	07-25-05	3.420		
01-03-05	2.320	08-01-05	3.477		
01-10-05	2.376	08-08-05	3.539		
01-18-05	2.407	08-15-05	3.549		
01-24-05	2.366	08-22-05	3.539		
01-31-05	2.525	08-29-05	3.575		
02-07-05	2.530	09-06-05	3.513		
02-14-05	2.592	09-12-05	3.529		
02-22-05	2.669	09-19-05	3.575		
02-28-05	2.772	09-26-05	3.518		

TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 139

TOPIC	RELEASE #
1A Drug Listing	11
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57
Allscrips Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110, 112
Bankruptcy - Drug Labelers	19, 61, 68
Best Price	
Effect of Sales to HMOs, etc.	137
To DSH Covered Entities	36
Under MPDIMA of 2003	128
Betaseron - Coverage & Reimbursement	38, 40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Compendia	70
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
Contact Information	65, 92
CPI-U Information	09, 102
Dataset Name Changes on Quarterly Rebate Tapes	41
Deleted Products-No Termination Date	139
Depot Prices-TRRx	137
DESI Code Change	137
Dipyridamole Issue	26
Dispute Resolution:	
Definition	19
E-Mail Address	128
Issues	55, 65, 71, 86, 108
Meetings	117, 123, 129, 132, 136, 138
Process Stages	45
Transfer of Function	121
Web Site	122
Workgroup Survey Results	42
Dispute Resolutions	59
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23, 24
DRUGDEX, a new compendium	70
Drug Emporium, Inc. Effective Date	65
Duplicate Discount/Rebate Mechanism Implementation	33
Effective Date(s) of Rebate Agreements	97
Enteral Nutritional Products - Coverage	30
Enteral Products	19

TOPIC

RELEASE #

Eon Labs Product	117
Experimental Drugs - Coverage	43
Failure of Manufacturers to Notify States of Disputes or Pay Rebates	63
FDA/MDRI Data Match	107, 115
Generic Substitution Laws	67
Goldline OTC Vitamin	102
Haldol Rebates	75
Heparin/Saline Flush Syringes & Other Non-Drug Products	132, 134, 136
Herceptin: Genentech New Product	85
HIPPA – Prescription Numbers	124
Hotline	53
HRSA Notice Published/Exclusion File	98, 101, 106
Improper Rebate Withholding/Interest Implications	114
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page	61, 85, 105, 117
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	26, 32, 128, 132
Lovenox Prefilled Syringes	91
LTE/IRS Drugs	26
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124, 137
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
MMA of 2003	128, 130
Multiple Package Size-Pricing Inconsistency	123
TOPIC	RELEASE #
New Drug Products	41

New Rebate Agreement Status	23
Non-Drug Products Coverage	132, 134
Non-Drug Products Deleted	123, 128, 132, 133, 134, 136, 137, 138, 139
Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120
Ortho Evra Replacement Patch	134
Overpayments Due to AMP Recalculations	57, 107
Personnel Changes	124, 130, 139
PHS Drug Pricing Program	44
Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations CMS-2175-FC	126
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Prices, Late Submission	33
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72, 130
Quarterly Update File	14
Questions and Answers	65
Rebate Agreements:	
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
Rebates:	
Calculation Formula	07
Drugs Purchased Through the FSS	113
Less than Administrative Costs	40
Nonpayment	94
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Recordkeeping Regulations	129
Regulation (CMS-2175-F)	136
Rejection of State Records Matching LTE Drugs	41
Remittance Advice Report/Workgroup	48, 52, 53, 56
Rescission of Termination for Novopharm USA	39
S-TAG (Systems Technical Advisory Group)	85
Separate Rebate Agreements with Manufacturers	38, 113
Special Advisory Group	16
Special Study – Anti-Load Viral/AIDS Drugs	102
Staff Listing	53
Staff Relocation	52, 83
TOPIC	RELEASE #

State Application of the FUL Program	48
State Contact Information	23, 26, 41, 98
State Coverage:	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Pharmacy Assistance Programs-Revised Criteria	124
State Plan Amendment Requirement	47
State Quarterly URA Tape	
Labeler Contact Information	134
Mailing	133
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
T-bill Rates	83, 86, 132
Termination Date (NDC)	79
Terminated/Deleted Records	44
Termination From Program	55
Therapeutic Equivalency Code	64
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Training Guide	
	130, 132, 133, 134, 136, 137, 138, 139
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Beohringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
First-Time Reporting on State Tape	132
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32, 83
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Receipt	29, 31

TOPIC

RELEASE #

Utilization Data:

Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
Record Format	08, 13, 72
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82
Transmitting Corrections/Adjustments to CMS	16, 40, 72
Utilization Discrepancy Report	139
Utilization Tape Record Specification	67, 72, 73, 98, 105
Vaccine:	
Deletions	26
Exclusions	19, 23
Policy Clarification	25
Viagra Coverage	81
Vitasert	64
Warrick Pharmaceuticals (Sodium Chloride Solution)	98
Xenical Coverage	97
Y2K	72, 87